Lupin has launched Levothyroxine Sodium Tablets USP, having received an approval from the United States Food and Drug Administration (USFDA) earlier. Lupin’s Levothyroxine Sodium Tablets USP, is the generic equivalent of AbbVie, Inc’s Synthroid Tablets. It is indicated for Hypothyroidism and Pituitary Thyrotropin Suppression.
Levothyroxine Sodium Tablets, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, and 300 mcg had an annual sales of approximately $2.5 billion in US (IQVIA MAT January 2019).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
